TriSalus Life Sciences initiated with a Buy at Roth MKM
The Fly

TriSalus Life Sciences initiated with a Buy at Roth MKM

Roth MKM analyst Jason Wittes initiated coverage of TriSalus Life Sciences (TLSI) with a Buy rating and $11 price target The company’s TriNav catheter significantly improves drug delivery with pressure enabled drug delivery, which is on its way to becoming the standard of care for delivering therapeutics to tumors in the liver, the analyst tells investors in a research note. The firm says this alone supports 50% growth through 2027, with upside from clinical expansion beyond the liver.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App